Skip to main content
Equibles
TECH logo

TECH · BIO-TECHNE Corp · Earnings Call Transcripts & Audio

Track TECH — free

Use TECH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TECH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$72.24 -0.02 (-0.02%)
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$11.33B
Shares
156.82M

BIO-TECHNE Corp Earnings Call Transcripts

Quarterly earnings calls for BIO-TECHNE Corp (TECH), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲4.6% $269.65M $89.56M '23 Q1 22-11-01 ▲0.9% $271.58M $50.01M '23 Q2 23-02-02 ▲1.3% $294.15M $70.22M '23 Q3 23-05-03 ▲4.5% $301.32M $75.48M '23 Q4 23-08-08 ▲2.7% $276.94M $50.99M '24 Q1 23-10-31 ▲0.4% $272.60M $27.46M '24 Q2 24-02-01 ▲3.2% $303.43M $49.06M '24 Q3 24-05-01 ▲1.6% $306.10M $40.59M '24 Q4 24-08-07 ▲4.5% $289.46M $33.60M '25 Q1 24-10-30 ▲9% $297.03M $34.89M '25 Q2 25-02-05 ▲4.2% $316.18M $22.59M '25 Q3 25-05-07 ▲3.5% $316.96M −$17.68M '25 Q4 25-08-06 ▼1% $286.56M $38.19M '26 Q1 25-11-05 ▼0.4% $295.88M $38.01M '26 Q2 26-02-04 ▼1.5% $311.42M $51.05M '26 Q3 26-05-06 LATEST ▲1.3% $321.19M $54.62M '26 Q4 26-08-12
Annual General Meeting
Investor event
2026-09-23
BIO-TECHNE Corp (TECH) September 2026 Annual General Meeting
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q4
2026-08-12
BIO-TECHNE Corp (TECH) Q4 2026 Earnings Call
Revenue
$321.19M*
▲ 1.3% YoY
Gross margin
65.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY26 · Q3
2026-05-06
BIO-TECHNE Corp (TECH) Q3 2026 Earnings Call Transcript
Positive tone Cell therapy and GMP proteins Spatial biology and Comet platform China and Asia end market
Revenue
$311.42M
▼ 1.5% YoY
Diluted EPS
$0.32
▲ 128.6% YoY
Gross margin
66.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-02-04
BIO-TECHNE Corp (TECH) Q2 2026 Earnings Call Transcript
Positive tone Cell therapy and Fast Track headwind Strategic growth verticals Margin expansion and operating leverage
Revenue
$295.88M
▼ 0.4% YoY
Diluted EPS
$0.24
▲ 9.1% YoY
Gross margin
64.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2025-11-05
BIO-TECHNE Corp (TECH) Q1 2026 Earnings Call Transcript
Positive tone Cell therapy clinical stage timing / Wilson Wolf Academic end market stabilization Spatial biology and China growth
Revenue
$286.56M
▼ 1% YoY
Diluted EPS
$0.24
▲ 14.3% YoY
Gross margin
65.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2025-08-06
BIO-TECHNE Corp (TECH) Q4 2025 Earnings Call Transcript
Positive tone Cell and gene therapy franchise China geographic performance Policy and tariff uncertainty
Revenue
$316.96M*
▲ 3.5% YoY
Gross margin
62.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-05-07
BIO-TECHNE Corp (TECH) Q3 2025 Earnings Call Transcript
Positive tone Pharma/biopharma end market recovery Tariffs and macro uncertainty NIH funding and US academic end-market uncertainty
Revenue
$316.18M
▲ 4.2% YoY
Diluted EPS
$0.14
▼ 54.8% YoY
Gross margin
67.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-02-05
BIO-TECHNE Corp (TECH) Q2 2025 Earnings Call Transcript
Confident tone China geographic headwind and outlook Spatial biology and multi-omic capabilities Cell therapy and GMP reagents
Revenue
$297.03M
▲ 9% YoY
Diluted EPS
$0.22
▲ 29.4% YoY
Gross margin
65.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2024-10-30
BIO-TECHNE Corp (TECH) Q1 2025 Earnings Call Transcript
Positive tone Biopharma end-market stabilization Cell and gene therapy / GMP reagents Spatial biology and molecular diagnostics
Revenue
$289.46M
▲ 4.5% YoY
Diluted EPS
$0.21
▼ 32.3% YoY
Gross margin
63.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-08-07
BIO-TECHNE Corp (TECH) Q4 2024 Earnings Call Transcript
Positive tone ProteinSimple / instrumentation franchise End market stabilization and recovery Growth verticals outperformance
Revenue
$306.10M*
▲ 1.6% YoY
Gross margin
66.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-05-01
BIO-TECHNE Corp (TECH) Q3 2024 Earnings Call Transcript
Confident tone China end market stabilization Spatial biology / Comet instrument Biopharma / biotech funding environment
Revenue
$303.43M
▲ 3.2% YoY
Diluted EPS
$0.31
▼ 27.9% YoY
Gross margin
67.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-02-01
BIO-TECHNE Corp (TECH) Q2 2024 Earnings Call Transcript
Positive tone China softness and stabilization Lunaphore acquisition and M&A pipeline CEO leadership transition
Revenue
$272.60M
▲ 0.4% YoY
Diluted EPS
$0.17
▼ 45.2% YoY
Gross margin
64.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2023-10-31
BIO-TECHNE Corp (TECH) Q1 2024 Earnings Call Transcript
Revenue
$276.94M
▲ 2.7% YoY
Diluted EPS
$0.31
▼ 43.6% YoY
Gross margin
66.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-08-08
BIO-TECHNE Corp (TECH) Q4 2023 Earnings Call Transcript
Revenue
$301.32M*
▲ 4.5% YoY
Gross margin
67.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-05-03
BIO-TECHNE Corp (TECH) Q3 2023 Earnings Call Transcript
Revenue
$294.15M
▲ 1.3% YoY
Diluted EPS
$0.43
▲ 16.2% YoY
Gross margin
68.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-02-02
BIO-TECHNE Corp (TECH) Q2 2023 Earnings Call Transcript
Revenue
$271.58M
▲ 0.9% YoY
Diluted EPS
$0.31
▼ 36.7% YoY
Gross margin
67.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2022-11-01
BIO-TECHNE Corp (TECH) Q1 2023 Earnings Call Transcript
Revenue
$269.65M
▲ 4.6% YoY
Diluted EPS
$0.55
▲ 30.2% YoY
Gross margin
66.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-08-04
BIO-TECHNE Corp (TECH) Q4 2022 Earnings Call Transcript
Revenue
$288.23M*
▲ 11.3% YoY
Gross margin
69.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-05-04
BIO-TECHNE Corp (TECH) Q3 2022 Earnings Call Transcript
Revenue
$290.38M
▲ 19.2% YoY
Diluted EPS
$0.37
▲ 32.1% YoY
Gross margin
69.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-02-01
BIO-TECHNE Corp (TECH) Q2 2022 Earnings Call Transcript
Revenue
$269.28M
▲ 20.1% YoY
Diluted EPS
$0.49
▲ 70.4% YoY
Gross margin
68.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2021-11-02
BIO-TECHNE Corp (TECH) Q1 2022 Earnings Call Transcript
Revenue
$257.72M
▲ 26.2% YoY
Diluted EPS
$0.42
▲ 103.6% YoY
Gross margin
66.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-08-05
BIO-TECHNE Corp (TECH) Q4 2021 Earnings Call Transcript
Revenue
$259.03M*
▲ 47.3% YoY
Gross margin
67.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-05-06
BIO-TECHNE Corp (TECH) Q3 2021 Earnings Call Transcript
Revenue
$243.55M
▲ 25.1% YoY
Diluted EPS
$0.28
▲ 21.7% YoY
Gross margin
69.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-02-02
BIO-TECHNE Corp (TECH) Q2 2021 Earnings Call Transcript
Revenue
$224.25M
▲ 21.3% YoY
Diluted EPS
$0.29
▼ 61.9% YoY
Gross margin
67.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2020-11-05
BIO-TECHNE Corp (TECH) Q1 2021 Earnings Call Transcript
Revenue
$204.20M
▲ 11.4% YoY
Diluted EPS
$0.21
▲ 124.3% YoY
Gross margin
67.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-08-04
BIO-TECHNE Corp (TECH) Q4 2020 Earnings Call Transcript
Revenue
$175.83M
▼ 8.3% YoY
Diluted EPS
$0.37
▲ 252.4% YoY
Gross margin
64.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-04-30
BIO-TECHNE Corp (TECH) Q3 2020 Earnings Call Transcript
Revenue
$194.68M
▲ 5.3% YoY
Diluted EPS
$0.23
▼ 20% YoY
Gross margin
66.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-02-04
BIO-TECHNE Corp (TECH) Q2 2020 Earnings Call Transcript
Revenue
$184.93M
▲ 6% YoY
Diluted EPS
$0.76
▲ 571.1% YoY
Gross margin
65.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2019-09-30
BIO-TECHNE Corp (TECH) Q1 2020 Earnings Call Transcript
Revenue
$183.24M
▲ 12.4% YoY
Diluted EPS
$0.09
▼ 17.8% YoY
Gross margin
64.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–29 of 29 earnings calls
Key facts CIK 842023 CUSIP 09073M104 13F (30d) 310 filings 309 filers Visit website Investor relations